Corcept Therapeutics (CORT) Reports Q4 2025 Earnings with Revenue Growth and Guidance Update
Corcept Therapeutics (CORT) reported Q4 2025 revenue of $761 million, up from $675 million in the previous year, driven by higher demand for Cushing’s syndrome treatments. The company provided 2026 revenue guidance of $900 million to $1 billion and reported net income of $99.7 million, down from $141.2 million, due to increased stock repurchase activity. The company also announced the onboarding of a new specialty pharmacy partner and progress in addressing prior bottlenecks.
Tickers: $CORT
Topics: earnings financial performance pharmacy transition revenue stock repurchase